REVITALIST LIFESTYLE WLNS - RVLWF STOCK NEWS

Revitalist has signed a lease for its 8th psychedelic assisted psychotherapy clinic in Bethesda, Maryland, which will span 6,092 square feet with 10 infusion rooms. The clinic is set to open by December 31, 2021, and aims to provide over 10,400 ketamine infusions annually. This expansion increases the Company’s total space to 53,792 square feet and 109 treatment rooms across its locations. CEO Kathryn Walker emphasizes the significance of being in Maryland, highlighting the region's medical institutions and the rising mental health crisis in the U.S.

Revitalist Lifestyle and Wellness Ltd. has announced the opening of its seventh clinic in Novi, Michigan. This facility will complement Revitalist's existing clinics and is expected to provide over 10,400 ketamine infusions annually, generating potential revenues of approximately $5.1 million at full capacity. With this new location, Revitalist's total revenue capacity reaches about $51.55 million, with annual gross margins estimated between $28.15 million and $32 million. The company has also engaged Hybrid Financial Ltd. for marketing services to enhance its visibility.

Revitalist Lifestyle and Wellness has acquired a 60% interest in Revitaland Meta Tech Inc. to develop virtual clinics in the metaverse through a partnership with Metachain Technologies Inc.. The collaborative effort aims to enhance mental health treatment options. As part of the agreement, Revitalist will issue common shares upon achieving specified development milestones, including launching a virtual clinic and generating $500,000 USD in revenue. This strategic move positions Revitalist to lead in virtual healthcare.

Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTC: RVLWF) has successfully closed a private placement, raising approximately Cdn$3,000,000.08. The Company issued 5,357,143 units at Cdn$0.56 per unit, each including a common share and a warrant. The warrants are exercisable at Cdn$0.69 until November 17, 2026. Proceeds will support working capital, clinic expansion, and corporate infrastructure. The placement was facilitated by H.C. Wainwright & Co., with a commission of Cdn$210,000.01 and additional warrants issued.

Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTC: RVLWF) reported approximately $1.55 million in clinic revenue for the ten months ending October 31, 2021, marking a 100% increase from $789,000 in 2020. This growth is attributed to organic expansion at its Knoxville, TN clinic and revenues from eight additional clinics across five states. The estimated gross margin is about $1.17 million. CEO Kathryn Walker stated that ongoing expansion and tailored marketing strategies are expected to drive continued growth into 2022 due to rising demand for mental health services.

Revitalist Lifestyle and Wellness Ltd. has announced a private placement agreement aimed at raising approximately Cdn$3 million through the issuance of 5,357,143 Units at Cdn$0.56 each. Each unit consists of a common share and a warrant, exercisable at Cdn$0.69 for five years. Proceeds will fund working capital and expand clinic operations in North America. The expected closing date is around November 17, 2021, subject to regulatory approvals.

Revitalist Lifestyle and Wellness (CSE: CALM, OTC: RVLWF) has announced a binding letter of intent with Metachain Technologies Inc. to establish virtual mental health clinics in the Metaverse. The initiative aims to enhance access to mental health services through real-time virtual sessions, cryptocurrency payments, and a rewards program utilizing NFTs. The collaboration emphasizes the global reach and efficiency of digital therapy while maintaining traditional therapies for specific conditions. This move aligns with the growing demand for accessible mental health solutions amid increasing societal challenges.

Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTC: RVLWF) has signed a binding letter of intent with MYND Diagnostics Inc. for a clinical research collaboration. This aims to study the relationship between diagnostic results using MYND's proprietary anti-inflammatory peptide biomarker (MAP) and improved patient outcomes in mental health. The initial clinical trials will focus on patients with post-COVID-19 mental health symptoms, utilizing Revitalist's network of over 2,300 patients. The goal is to submit MAP to the FDA for approval in Q2 2022, enhancing diagnostic accuracy and treatment efficacy.

Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTC: RVLWF) is partnering with the US Department of Veterans Affairs to provide mental health services for veterans suffering from treatment-resistant conditions. The initiative comes in response to a crisis with over 65,000 veteran suicides since 2010. The company has a strong focus on veteran health, led by experienced military professionals, aiming to offer comprehensive care in a supportive environment. CEO Kathryn Walker emphasizes their commitment to honoring veterans through quality care.